Abstract
Background: Systemic chemotherapy is the main treatment of diffuse and/or aggressive classic Kaposi’s sarcoma (KS) but there are no standard treatment guidelines and published literature regarding vinorelbine is lacking. Objectives: To assess the safety and effectiveness of intra-venous vinorelbine in the treatment of classic KS. Materials & methods: We performed a retrospective study of a departmental database in histologically proven classic KS. Results: Twenty patients received intra- venous vinorelbine as cycles of 20 mg/m2 once every two weeks for 5 cycles and subsequently at a dose of 30 mg/m2 once every three weeks. Of 19 assessable patients, three (16%) had a complete remission and 11 (58%) had a partial response, for an overall response rate of 74%. The remaining 5 patients had a stable disease (26%). Grade 3 or 4 toxicities were neutropenia (3/20 patients), deep vein thrombosis (1/20 patients) and constipation (1/20 patients). The median progression-free survival from the start of therapy until the development of progressive disease was 35.1 months. Conclusion: Vinorelbine is an effective and overall well tolerated treatment for classic KS.
| Original language | English |
|---|---|
| Pages (from-to) | 535-538 |
| Number of pages | 4 |
| Journal | European Journal of Dermatology |
| Volume | 25 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Nov 1 2015 |
Fingerprint
Keywords
- Chemotherapy
- Intravenous vinorelbine
- Kaposi’s sarcoma
- Treatment
ASJC Scopus subject areas
- Dermatology
Cite this
Vinorelbine therapy in classic Kaposi’s sarcoma : A retrospective study of 20 patients. / Brambilla, Lucia; Recalcati, Sebastiano; Tourlaki, Athanasia.
In: European Journal of Dermatology, Vol. 25, No. 6, 01.11.2015, p. 535-538.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Vinorelbine therapy in classic Kaposi’s sarcoma
T2 - A retrospective study of 20 patients
AU - Brambilla, Lucia
AU - Recalcati, Sebastiano
AU - Tourlaki, Athanasia
PY - 2015/11/1
Y1 - 2015/11/1
N2 - Background: Systemic chemotherapy is the main treatment of diffuse and/or aggressive classic Kaposi’s sarcoma (KS) but there are no standard treatment guidelines and published literature regarding vinorelbine is lacking. Objectives: To assess the safety and effectiveness of intra-venous vinorelbine in the treatment of classic KS. Materials & methods: We performed a retrospective study of a departmental database in histologically proven classic KS. Results: Twenty patients received intra- venous vinorelbine as cycles of 20 mg/m2 once every two weeks for 5 cycles and subsequently at a dose of 30 mg/m2 once every three weeks. Of 19 assessable patients, three (16%) had a complete remission and 11 (58%) had a partial response, for an overall response rate of 74%. The remaining 5 patients had a stable disease (26%). Grade 3 or 4 toxicities were neutropenia (3/20 patients), deep vein thrombosis (1/20 patients) and constipation (1/20 patients). The median progression-free survival from the start of therapy until the development of progressive disease was 35.1 months. Conclusion: Vinorelbine is an effective and overall well tolerated treatment for classic KS.
AB - Background: Systemic chemotherapy is the main treatment of diffuse and/or aggressive classic Kaposi’s sarcoma (KS) but there are no standard treatment guidelines and published literature regarding vinorelbine is lacking. Objectives: To assess the safety and effectiveness of intra-venous vinorelbine in the treatment of classic KS. Materials & methods: We performed a retrospective study of a departmental database in histologically proven classic KS. Results: Twenty patients received intra- venous vinorelbine as cycles of 20 mg/m2 once every two weeks for 5 cycles and subsequently at a dose of 30 mg/m2 once every three weeks. Of 19 assessable patients, three (16%) had a complete remission and 11 (58%) had a partial response, for an overall response rate of 74%. The remaining 5 patients had a stable disease (26%). Grade 3 or 4 toxicities were neutropenia (3/20 patients), deep vein thrombosis (1/20 patients) and constipation (1/20 patients). The median progression-free survival from the start of therapy until the development of progressive disease was 35.1 months. Conclusion: Vinorelbine is an effective and overall well tolerated treatment for classic KS.
KW - Chemotherapy
KW - Intravenous vinorelbine
KW - Kaposi’s sarcoma
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=84957889034&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84957889034&partnerID=8YFLogxK
U2 - 10.1684/ejd.2015.2659
DO - 10.1684/ejd.2015.2659
M3 - Article
AN - SCOPUS:84957889034
VL - 25
SP - 535
EP - 538
JO - European Journal of Dermatology
JF - European Journal of Dermatology
SN - 1167-1122
IS - 6
ER -